Currently, SOTIO is conducting a Phase 1 clinical trial of SOT201, a next-generation PD-1-targeting immunocytokine. The VICTORIA-01 study is assessing the safety, tolerability, and preliminary efficacy of SOT201 as a monotherapy for patients aged 18 years or above with advanced unresectable or metastatic solid tumors (NCT06163391).